Viridian Therapeutics
(NASDAQ:VRDN)
$17.51
0[0.00%]
At close: Mar 28
$17.51
0[0.00%]
After Hours: 4:05PM EDT
Consensus Rating1
Outperform
Highest Price Target1
$51.00
Lowest Price Target1
$25.00
Consensus Price Target1
$38.63

Viridian Therapeutics Stock (NASDAQ:VRDN), Analyst Ratings, Price Targets, Predictions

Viridian Therapeutics Inc has a consensus price target of $38.63, established from looking at the 53 latest analyst ratings. The last 3 analyst ratings were released from B. Riley Securities, Needham, and HC Wainwright & Co. on March 21, 2024, March 20, 2024, and February 29, 2024. With an average price target of $30.67 between B. Riley Securities, Needham, and HC Wainwright & Co., there's an implied 75.14% upside for Viridian Therapeutics Inc from these 3 analyst ratings.

Analyst Rating Summary1

Analyst Ratings
Oct 23
3
Nov 23
1
Dec 23
4
Feb
3
Mar
2
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

B. Riley Securities
Needham
HC Wainwright & Co.
Wedbush
Oppenheimer

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Viridian Therapeutics

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
03/21/2024VRDNBuy Now
Viridian Therapeutics
$17.5142.78%B. Riley Securities
Kalpit Patel
$29 → $25MaintainsBuyGet Alert
03/20/2024VRDNBuy Now
Viridian Therapeutics
$17.5171.33%Needham
Serge Belanger
$30 → $30MaintainsBuyGet Alert
02/29/2024VRDNBuy Now
Viridian Therapeutics
$17.51111.31%HC Wainwright & Co.
Douglas Tsao
→ $37ReiteratesBuy → BuyGet Alert
02/28/2024VRDNBuy Now
Viridian Therapeutics
$17.51128.44%Wedbush
Laura Chico
$39 → $40MaintainsOutperformGet Alert
02/28/2024VRDNBuy Now
Viridian Therapeutics
$17.5171.33%Needham
Serge Belanger
→ $30ReiteratesBuy → BuyGet Alert
12/19/2023VRDNBuy Now
Viridian Therapeutics
$17.51105.6%Oppenheimer
Leland Gershell
$35 → $36MaintainsOutperformGet Alert
12/18/2023VRDNBuy Now
Viridian Therapeutics
$17.51111.31%HC Wainwright & Co.
Douglas Tsao
→ $37ReiteratesBuy → BuyGet Alert
12/14/2023VRDNBuy Now
Viridian Therapeutics
$17.5199.89%RBC Capital
Gregory Renza
→ $35ReiteratesOutperform → OutperformGet Alert
12/04/2023VRDNBuy Now
Viridian Therapeutics
$17.51111.31%Wedbush
Laura Chico
→ $37ReiteratesOutperform → OutperformGet Alert
11/14/2023VRDNBuy Now
Viridian Therapeutics
$17.5199.89%RBC Capital
Gregory Renza
→ $35ReiteratesOutperform → OutperformGet Alert
11/14/2023VRDNBuy Now
Viridian Therapeutics
$17.51117.02%JMP Securities
Jason Butler
$42 → $38MaintainsMarket OutperformGet Alert
10/31/2023VRDNBuy Now
Viridian Therapeutics
$17.5199.89%RBC Capital
Gregory Renza
$44 → $35MaintainsOutperformGet Alert
10/31/2023VRDNBuy Now
Viridian Therapeutics
$17.51111.31%Wedbush
Laura Chico
$46 → $37MaintainsOutperformGet Alert
10/30/2023VRDNBuy Now
Viridian Therapeutics
$17.5171.33%Needham
Serge Belanger
$40 → $30MaintainsBuyGet Alert
09/13/2023VRDNBuy Now
Viridian Therapeutics
$17.51128.44%Stifel
Alex Thompson
→ $40ReiteratesBuy → BuyGet Alert
09/13/2023VRDNBuy Now
Viridian Therapeutics
$17.51162.71%Wedbush
Laura Chico
→ $46ReiteratesOutperform → OutperformGet Alert
08/10/2023VRDNBuy Now
Viridian Therapeutics
$17.51111.31%HC Wainwright & Co.
Douglas Tsao
$40 → $37MaintainsBuyGet Alert
08/10/2023VRDNBuy Now
Viridian Therapeutics
$17.51128.44%Needham
Serge Belanger
$47 → $40MaintainsBuyGet Alert
08/09/2023VRDNBuy Now
Viridian Therapeutics
$17.51139.86%JMP Securities
Jason Butler
$44 → $42MaintainsMarket OutperformGet Alert

FAQ

Q

What is the target price for Viridian Therapeutics (VRDN)?

A

The latest price target for Viridian Therapeutics (NASDAQ: VRDN) was reported by B. Riley Securities on March 21, 2024. The analyst firm set a price target for $25.00 expecting VRDN to rise to within 12 months (a possible 42.78% upside). 38 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Viridian Therapeutics (VRDN)?

A

The latest analyst rating for Viridian Therapeutics (NASDAQ: VRDN) was provided by B. Riley Securities, and Viridian Therapeutics maintained their buy rating.

Q

When was the last upgrade for Viridian Therapeutics (VRDN)?

A

There is no last upgrade for Viridian Therapeutics.

Q

When was the last downgrade for Viridian Therapeutics (VRDN)?

A

There is no last downgrade for Viridian Therapeutics.

Q

When is the next analyst rating going to be posted or updated for Viridian Therapeutics (VRDN)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Viridian Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Viridian Therapeutics was filed on March 21, 2024 so you should expect the next rating to be made available sometime around March 21, 2025.

Q

Is the Analyst Rating Viridian Therapeutics (VRDN) correct?

A

While ratings are subjective and will change, the latest Viridian Therapeutics (VRDN) rating was a maintained with a price target of $29.00 to $25.00. The current price Viridian Therapeutics (VRDN) is trading at is $17.51, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch